Dr. Connolly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1Tower Place
#300
South San Francisco, CA 94080
Education & Training
University of WashingtonFellowship, Infectious Disease, 2003 - 2005
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2001 - 2003
University of California San Francisco School of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2002 - 2026- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 473 citationsAminoglycosides: An OverviewKevin M. Krause, Alisa W Serio, Timothy R. Kane, Lynn E. Connolly
Cold Spring Harbor Perspectives in Medicine. 2016-06-01 - 388 citationsDrug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.Kristin N. Adams, Kevin K. Takaki, Lynn E. Connolly, Heather Wiedenhoft, Kathryn Winglee
Cell. 2011-04-01 - 149 citationsWhy is long-term therapy required to cure tuberculosis?Lynn E. Connolly, Paul H. Edelstein, Lalita Ramakrishnan
Plos Medicine. 2007-03-20
Press Mentions
Adagio Therapeutics Launches with $50M Series A Financing to Advance the Development of Best-in-Class, Broadly Neutralizing Antibodies for Coronavirus Treatment and ProphylaxisJuly 16th, 2020
Grant Support
- Biofilm Formation In Mycobacterial Persistence And Drug Tolerance In VivoNational Institute Of Allergy And Infectious Diseases2008–2010
- Biofilm Formation In Mycobacterial Persistence And Drug Tolerance In VivoNational Institute Of Allergy And Infectious Diseases2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
